Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 21.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,684 shares of the company’s stock after purchasing an additional 475 shares during the period. Nisa Investment Advisors LLC’s holdings in Vaxcyte were worth $220,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Riverview Trust Co purchased a new stake in Vaxcyte in the 3rd quarter worth approximately $27,000. Blue Trust Inc. raised its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the period. Meeder Asset Management Inc. lifted its stake in shares of Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after purchasing an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Vaxcyte in the third quarter worth about $92,000. Finally, Signaturefd LLC grew its position in Vaxcyte by 51.9% in the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after acquiring an additional 358 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PCVX. Needham & Company LLC reissued a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $145.71.

Insider Activity

In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of the firm’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $91.49, for a total transaction of $457,450.00. Following the completion of the sale, the senior vice president now directly owns 28,697 shares in the company, valued at approximately $2,625,488.53. This trade represents a 14.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Grant Pickering sold 2,366 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the sale, the chief executive officer now owns 137,398 shares of the company’s stock, valued at approximately $14,274,278.22. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 85,982 shares of company stock worth $8,108,425. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX opened at $88.67 on Thursday. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The stock has a fifty day moving average price of $87.48 and a 200 day moving average price of $94.24. The company has a market cap of $11.05 billion, a P/E ratio of -19.28 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the firm earned ($0.91) EPS. As a group, research analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.